Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cholangiocarcinoma 2Upper Tract Urothelial Carcinomas 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Renal Pelvis and Ureter Urothelial Carcinoma 1Papillomavirus Infections 1Oncogenic osteomalacia 1Nasopharyngeal Neoplasms 1Hypophosphatemia 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Breast Neoplasms 1

Interventions

Capecitabine 27pembrolizumab 19Oxaliplatin 19Fluorouracil 17Cisplatin 17Trastuzumab 14Docetaxel 14Leucovorin 11Paclitaxel 8Irinotecan 8S 1 (combination) 7Epirubicin 6Cyclophosphamide 5tegafur-gimeracil-oteracil 4aldesleukin 4Hyperthermic Intraperitoneal Chemotherapy 4titanium silicide 3spartalizumab 3fludarabine phosphate 3fludarabine 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Ramucirumab 3Nivolumab 3Indocyanine Green 3Gemcitabine 3Carboplatin 3Albumin-Bound Paclitaxel 3Ado-Trastuzumab Emtansine 3vistusertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Stomach Neoplasms × infigratinib × Clear all
NCT06206278 2024-08-14

Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

LianBio LLC

Phase 2 Terminated
6 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡